Drugs / VRC-HIVMAB0121-00-AB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06585891 | Oct 2024 → Sep 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-HIVMAB0121-00-AB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06585891 ↗ |
| Known as | CAP256J3LS | “Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults” NCT06585891 ↗ |
| Route | Intravenous | “administered intravenously or subcutaneously” NCT06585891 ↗ |
| Route | Subcutaneous | “administered intravenously or subcutaneously” NCT06585891 ↗ |